Sep 11, 2023 / 04:55PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Great. Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. Biopharma Analyst here at Morgan Stanley. Very pleased to have United Therapeutics with us.
Before we get started, I have to read a disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Joining us today from the company, we have James Edgemond, who is the company's CFO; and Dewey Steadman, who is Head of Investor Relations. Thank you, both for being here. Really appreciate it.
Dewey, I'm going to turn it over to you for your disclosures, and then we'll get started.
Dewey Steadman - United Therapeutics Corporation - Head of IR
Thanks, Terence. I appreciate it, and good afternoon, everyone. Just as a reminder, remarks today that
United Therapeutics Corp at Morgan Stanley Global Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers